Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.

We report a rare case of gastric cancer with liver metastasis in a patient whose condition improved with the combination use of lenvatinib and camrelizumab. A 53-year-old man was admitted to hospital for abdominal pain. After an enhanced CT scan of his abdomen, it was found that he had multiple liver occupancy. Gastroscopic biopsies and liver biopsies supported the clinical diagnosis of stage IV gastric cancer. Next-generation sequencing technology (NGS) testing indicated that the tumor mutational burden (TMB) of the liver tissue and stomach tissue samples were high. The patient first received transcatheter arterial chemoembolization (TACE) treatment on August 30, 2018. The patient later received combined lenvatinib (8 mg, daily) anti-angiogenic therapy and camrelizumab (200 mg, every 2 weeks) immunotherapy. Three months following treatment, the patient's abdominal pain was relieved and his weight was increased. Regular reexamination of CT showed that the metastases of the liver continued to shrink. The curative effect was evaluated as partial response (PR). After 11 months of treatment, gastroscopy showed that the lesions of gastric tumors disappeared. At present, 14 months since the initial treatment, there is no clinical evidence of disease progression, and the current overall survival time is 14 months. Moreover, the quality of life of the patient was good and there were no obvious adverse drug reactions. This suggests that immunotherapy combined with antiangiogenic therapy has a synergistic effect on tumor and can play a better anti-tumor effect.